PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medical Oncology, Centre Hospitalier, Antibes, France. daniel.re@ch-antibes.fr.\', \'Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France. daniel.re@ch-antibes.fr.\', \'Laboratoire d\'Immunologie, Centre Hospitalier Universitaire (CHU) de Nice, Université Côte d\'Azur, Nice, France.\', \'Unité de Recherche Clinique de la Côte d\'Azur (UR2CA), Université Côte d\'Azur, Nice, France.\', \'Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, CHU de Nice, Université Côte d\'Azur, Nice, France.\', \'Department of Infectious Disease, Centre Hospitalier Universitaire de Nice (CHU), Nice, France.\', \'INSERM, C3M, Université Côte d\'Azur, Nice, France.\', \'Department of Medical Biology, Centre Hospitalier, Antibes, France.\', \'Department of Pharmacy, Centre Hospitalier, Antibes, France.\', \'Department of Biostatistics and Epidemiology, Centre Antoine Lacassagne, Nice, France.\', \'Department of Medical Oncology, Polyclinique Saint-Jean, Cagnes-sur-Mer, France. j.barriere@polesantesaintjean.fr.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1038/s41467-022-28578-0
?:doi
?:hasPublicationType
?:journal
  • Nature communications
is ?:pmid of
?:pmid
?:pmid
  • 35165284
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 6.582
?:rankingScore_hIndex
  • 198
is ?:relation_isRelatedTo_publication of
?:title
  • Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.
?:type
?:year
  • 2022

Metadata

Anon_0  
expand all